Literature DB >> 16696074

c-erbB3 protein expression in ovarian cancer.

T Rajkumar1, G W Stamp, C M Hughes, W J Gullick.   

Abstract

Aims-To study the prevalence of overexpression of c-erbB3 growth factor receptor in ovarian carcinomas and to analyse its relation to histological subtype, stage and grade of the tumours.Methods-Ninety eight ovarian carcinomas were evaluated immunohistochemically using the RTJ1 monoclonal antibody raised against a synthetic peptide, the sequence of which was derived from the cytoplasmic domain of the c-erbB3 protein.Results-Of the tumours, 16% (16/98) overexpressed c-erbB3 protein relative to normal ovarian epithelium, whereas 22% (22/98) were completely negative. There was a statistically significant association between overexpression and well differentiated grade.Conclusions-These findings suggest that c-erbB3 protein overexpression occurs in a significant proportion of ovarian cancers and is correlated with differentiation. Overexpression may merit further investigation as a potential prognostic indicator and as a target for new treatment.

Entities:  

Year:  1996        PMID: 16696074      PMCID: PMC408058          DOI: 10.1136/mp.49.4.m199

Source DB:  PubMed          Journal:  Clin Mol Pathol        ISSN: 1355-2910


  33 in total

1.  c-erbB-2 oncogene expression in ovarian cancer.

Authors:  J S Haldane; V Hird; C M Hughes; W J Gullick
Journal:  J Pathol       Date:  1990-11       Impact factor: 7.996

2.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Authors:  D J Riese; T M van Raaij; G D Plowman; G C Andrews; D F Stern
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Amplification of HER-2/neu oncogene in human ovarian cancer.

Authors:  J A Leary; B G Edwards; C R Houghton; R F Kefford; M L Friedlander
Journal:  Int J Gynecol Cancer       Date:  1992-11       Impact factor: 3.437

5.  Expression of the c-erbB-3 gene product in gastric cancer.

Authors:  E E Sanidas; M I Filipe; J Linehan; N R Lemoine; W J Gullick; T Rajkumar; D A Levison
Journal:  Int J Cancer       Date:  1993-07-30       Impact factor: 7.396

6.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Authors:  R R Beerli; D Graus-Porta; K Woods-Cook; X Chen; Y Yarden; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

7.  Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

Authors:  R B Myers; S Srivastava; D K Oelschlager; W E Grizzle
Journal:  J Natl Cancer Inst       Date:  1994-08-03       Impact factor: 13.506

8.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

9.  c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.

Authors:  G Gasparini; W J Gullick; S Maluta; P Dalla Palma; O Caffo; E Leonardi; P Boracchi; F Pozza; N R Lemoine; P Bevilacqua
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

10.  A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines.

Authors:  T Rajkumar; W J Gullick
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more
  18 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model.

Authors:  John S Schardt; Madeleine Noonan-Shueh; Jinan M Oubaid; Alex Eli Pottash; Sonya C Williams; Arif Hussain; Rena G Lapidus; Stanley Lipkowitz; Steven M Jay
Journal:  AAPS J       Date:  2019-04-04       Impact factor: 4.009

Review 3.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors:  Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

Review 4.  HER3 in cancer: from the bench to the bedside.

Authors:  Lucía Gandullo-Sánchez; Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2022-10-21

5.  Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.

Authors:  Daekee Lee; Ming Yu; Eunjung Lee; Hyunok Kim; Yanan Yang; Kyoungmi Kim; Christina Pannicia; Jonathan M Kurie; David W Threadgill
Journal:  J Clin Invest       Date:  2009-08-17       Impact factor: 14.808

Review 6.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  EGF and TGF-β1 Effects on Thyroid Function.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Caterina Francesca Donini; Anna Coppa
Journal:  J Thyroid Res       Date:  2011-06-13

Review 9.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Authors:  Luigi Aurisicchio; Emanuele Marra; Giuseppe Roscilli; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2012-08

10.  Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Authors:  M K Robinson; K M Hodge; E Horak; A L Sundberg; M Russeva; C C Shaller; M von Mehren; I Shchaveleva; H H Simmons; J D Marks; G P Adams
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.